Zura Bio Limited filed a Form 8-K on November 9, 2026, disclosing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.

Key Highlights

  • Clinical update issued: Zura Bio released a press release on November 9, 2026, providing a clinical update on the Phase 2 TibuSHIELD study.
  • Drug candidate: The study involves tibulizumab, designated ZB-106, a compound being evaluated by the company.
  • Target population: The TibuSHIELD study enrolls adults with moderate-to-severe hidradenitis suppurativa, according to the filing.
  • Registrant identity: Zura Bio Limited is incorporated as a Cayman Islands exempted company, listed on NASDAQ:ZURA.
  • Emerging growth company: The company indicated it qualifies as an emerging growth company under applicable SEC rules.
  • Signed by CEO: The filing was signed by Sandeep Kulkarni, identified as Chief Executive Officer.

Zura Bio's TibuSHIELD Study: What the Filing Covers

According to the Form 8-K filed under Item 8.01 (Other Events), Zura Bio Limited issued a press release on November 9, 2026, providing a clinical update on the ongoing Phase 2 TibuSHIELD study. The study is evaluating tibulizumab, internally designated ZB-106, in adults diagnosed with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin condition. The press release was attached to the filing as Exhibit 99.1 and incorporated by reference.

Zura Bio Limited is a Cayman Islands exempted company with its principal executive offices located at 1489 W. Warm Springs Rd., #110, Henderson, NV 89014. Its Class A Ordinary Shares, with a par value of $0.0001 per share, are listed on The Nasdaq Stock Market LLC under the trading symbol NASDAQ:ZURA. The company disclosed that it qualifies as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, though it has not elected to use the extended transition period for complying with new or revised financial accounting standards.

The filing did not include financial statements or financial data. It was filed pursuant to Item 8.01 (Other Events) of Form 8-K, with the only exhibit being the press release dated November 9, 2026 (Exhibit 99.1), along with a Cover Page Interactive Data File embedded within the Inline XBRL document (Exhibit 104). The filing was signed by Sandeep Kulkarni in his capacity as Chief Executive Officer on November 9, 2026.

What Was Disclosed

Zura Bio Limited filed a Form 8-K on November 9, 2026, reporting a clinical update on the Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in moderate-to-severe hidradenitis suppurativa patients. The underlying press release was attached as Exhibit 99.1.